Should FDA Require Drug Manufacturers to Test Effects of New Drugs on Varying Populations?

Jan 4, 2011, 6:58 PM, Posted by

RWJF Scholars in Health Policy Research National Program Director Alan B. Cohen, Sc.D., had a letter in the December 29, 2010 New York Times (Avastin: Judging the Risks vs. Benefits), noting that Food & Drug Administration (FDA) approval of new drugs “commonly opens the floodgates to widespread use, often by many patients for whom the benefits are questionable.” Cohen argues that the FDA and the manufacturers of new drugs “should be required to consider the varying effects of a new drug on different groups of people so that drug approval decisions can be targeted at those who will really benefit while preventing or minimizing adverse effects for those who won’t.”

This commentary originally appeared on the RWJF Human Capital Blog. The views and opinions expressed here are those of the authors.